{"product_id":"targeted-therapy-in-translational-cancer-research-isbn-9781118468579","title":"Targeted Therapy in Translational Cancer Research","description":"\u003ci\u003eTargeted Therapy in Translational Cancer Research\u003c\/i\u003e for the \u003ci\u003eTranslational Oncology\u003c\/i\u003e series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy.\u003cbr\u003e\u003cbr\u003e \u003cul\u003e \u003cli\u003eIntroduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer\u003c\/li\u003e \u003cli\u003eCovers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine\u003c\/li\u003e \u003cli\u003eSummarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eList of Contributors, vii\u003c\/p\u003e \u003cp\u003eSeries Foreword, xiii\u003c\/p\u003e \u003cp\u003eForeword, xv\u003c\/p\u003e \u003cp\u003ePreface, xvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Principles of Targeted Therapies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Toward Personalized Therapy for Cancer, 3\u003cbr\u003e\u003ci\u003eAshley M. Holder and FundaMeric-Bernstam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Combining Targeted Therapies, 14\u003cbr\u003e\u003ci\u003eJordi Rodon, Analia Azaro, Davis Torrejon, and Razelle Kurzrock\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Principles of Targeted Immunotherapy, 27\u003cbr\u003e\u003ci\u003eSusanne H. C. Baumeister and Glenn Dranoff\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Cancer Stem Cell Principles, 39\u003cbr\u003e\u003ci\u003eAllison C. Sharrow, Gabriel Ghiaur, and Richard J. Jones\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 The Tumor Microenvironment as a Target for Therapeutic Intervention, 47\u003cbr\u003e\u003ci\u003eHua Fang and Yves A. DeClerck\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 The Role of Angiogenesis in Cancer, 64\u003cbr\u003e\u003ci\u003eMorgan Taylor, Robert L. Coleman, and Anil K. Sood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Epigenetics and Epigenetic Therapy of Cancer, 72\u003cbr\u003e\u003ci\u003eOmotayo Fasan, Patrick Boland, PatriciaKropf, and Jean-Pierre J. Issa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 The Role of microRNAs in Cancer, 80\u003cbr\u003e\u003ci\u003eGianpiero Di Leva and Carlo M. Croce\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 AcuteMyeloidLeukemia, 89\u003cbr\u003e\u003ci\u003eOfir Wolach and Richard M. Stone\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Targeted and Functional Imaging, 101\u003cbr\u003e\u003ci\u003eJian Q. (Michael) Yu, Drew A. Torigian, and Abass Alavi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Targeted Therapy in Hematological Malignancies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11 Targeted Therapies in Chronic Myeloid Leukemia, 113\u003cbr\u003e\u003ci\u003eElias Jabbour and Jorge Cortes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Targeted Therapy for Acute Lymphoblastic Leukemia, 121\u003cbr\u003e\u003ci\u003eNitin Jain, Susan O’Brien, and Farhad Ravandi-Kashani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Chronic Lymphocytic Leukemia, 130\u003cbr\u003e\u003ci\u003ePreetesh Jain and Susan O’Brien\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Multiple Myeloma, 145\u003cbr\u003e\u003ci\u003eGiada Bianchi and Kenneth C. Anderson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 The Impact of Genomics on Targeted Therapy in Multiple Myeloma and Lymphomas, 157\u003cbr\u003e\u003ci\u003eJens G. Lohr and Birgit Knoechel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Targeted Therapy in Myelodysplastic Syndromes, 162\u003cbr\u003e\u003ci\u003eGuillermo Montalb´an-Bravo and Guillermo Garc´ýa-Manero\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Lymphoma and Targeted Therapies, 169\u003cbr\u003e\u003ci\u003eSonali M. Smith and Julie M. Vose\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Targeted Therapy in Solid Tumors\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 Targeted Therapy in Solid Tumors: Brain, 179\u003cbr\u003e\u003ci\u003eShiao-PeiWeathers, Barbara J. O’Brien, John F. de Groot, andW. K. Alfred Yung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Targeted Therapy for Breast Cancer, 190\u003cbr\u003e\u003ci\u003eHarold J. Burstein\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Targeted Therapy in Solid Tumors: Colorectal Cancer, 193\u003cbr\u003e\u003ci\u003eMaen Abdelrahim, Scott Kopetz, and David Menter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Endometrial Cancer, 205\u003cbr\u003e\u003ci\u003eJessica L. Bowser, Russell R. Broaddus, Robert L. Coleman, and Shannon N. Westin\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Targeted Therapy in Solid Tumors: Head and Neck, 216\u003cbr\u003e\u003ci\u003eMarcus M. Monroe and Jeffrey N. Myers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Targeted Therapy in Solid Tumors: Lung Cancer, 224\u003cbr\u003e\u003ci\u003eSaiama N.Waqar, Daniel Morgensztern, and Roy S. Herbst\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Targeted Therapy in Melanoma, 231\u003cbr\u003e\u003ci\u003eKeith T. Flaherty\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Ovarian Cancer, 240\u003cbr\u003e\u003ci\u003eShannon N.Westin, Larissa A. Meyer, and Robert L. Coleman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Molecular Therapeutics: Pancreatic Cancer, 255\u003cbr\u003e\u003ci\u003eDavid Fogelman, Milind Javle, and James Abbruzzese\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Targeted Therapies for Pediatric Solid Tumors, 263\u003cbr\u003e\u003ci\u003eJasmine Quynh Dao and Patrick A. Zweidler-McKay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Prostate Cancer, 273\u003cbr\u003e\u003ci\u003eWilliam G. Nelson, Michael C. Haffner, and Srinivasan Yegnasubramanian\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Renal Cell Carcinoma and Targeted Therapy, 287\u003cbr\u003e\u003ci\u003eBenjamin A. Gartrell, Alexander C. Small, William K. Oh, and Matthew D. Galsky\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Targeted Therapy in Solid Tumors: Sarcomas, 296\u003cbr\u003e\u003ci\u003eAnthony P. Conley, Vinod Ravi, and Shreyaskumar Patel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Targeted Therapy for Specific Molecular Aberrations\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e31 RAS-RAF-MEK Pathway: Aberrations and Therapeutic Possibilities, 305\u003cbr\u003e\u003ci\u003eJavier Munoz and Filip Janku\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 The Phosphatidylinositol 3-Kinase Pathway in Human Malignancies, 315\u003cbr\u003e\u003ci\u003eSamuel J. Klempner,Thanh-Trang Vo, Andrea P. Myers, and Lewis C. Cantley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Current Status and Future Direction of PARP Inhibition in Cancer Therapy, 325\u003cbr\u003e\u003ci\u003eSaeed Rafii, Stan Kaye and Susana Banerjee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Targeting the c-Met Kinase, 341\u003cbr\u003e\u003ci\u003eChad Tang, M. Angelica Cortez, David Hong, and James W. Welsh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 KIT Kinase, 347\u003cbr\u003e\u003ci\u003eScott E. Woodman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 TP53, 353\u003cbr\u003e\u003ci\u003eKensuke Kojima and Michael Andreeff\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Future Perspectives\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e37 Future Perspectives, 363\u003cbr\u003e\u003ci\u003eRabih Said and Apostolia-Maria Tsimberidou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 371\u003c\/p\u003e Apostolia-Maria Tsimberidou, MD PhD\u003cbr\u003eDepartment of Investigational Cancer Therapeutics\u003cbr\u003eThe University of Texas MD Anderson Cancer Center\u003cbr\u003eHouston, TX, USA\u003cbr\u003e\u003cbr\u003eRazelle Kurzrock\u003cbr\u003eCenter for Personalized Cancer Therapy, UC San Diego - Moores Cancer Center\u003cbr\u003eLa Jolla, CA, USA\u003cbr\u003e\u003cbr\u003eKenneth C. Anderson MD\u003cbr\u003eLeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School\u003cbr\u003eBoston, MA, USA \u003cp\u003eIn the last decade, emergent technologies have enhanced our understanding of genomic, transcriptional, proteomic, epigenetic, and immune mechanisms in carcinogenesis. This improved understanding has enabled the development of targeted cancer therapies and personalized management, and transformed conventional treatment paradigms. It has provided the framework for the discovery of new targets, for validation of novel agents, for combination therapies predicated upon scientific rationale, and for clinical trials that have already markedly improved the prognosis and outcome of patients with cancer.\u003cbr\u003e\u003cbr\u003eOver 37 chapters this volume of \u003ci\u003eTranslational Oncology\u003c\/i\u003e series, \u003ci\u003eTargeted Therapy in Translational Cancer Research\u003c\/i\u003e:\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIntroduces the cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer\u003c\/li\u003e \u003cli\u003eProvides a comprehensive overview of recent developments in our understanding of tumor biology and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy\u003c\/li\u003e \u003cli\u003eCovers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine\u003c\/li\u003e \u003cli\u003eSummarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cbr\u003eWe are on the threshold of translating discoveries in cancer biology into unprecedented durable responses and improved clinical outcomes in the majority of patients with cancer. In this unique time in history, the discovery of novel therapeutic approaches targeting the molecular basis of cancer will allow for implementation of precision medicine, with the promise of potentially curative, well tolerated, therapies. Targeted Therapy in Translational Cancer Research was written to increase the awareness and access of basic and clinical researchers, caregivers, and patients alike to cutting-edge “bench to bedside and back” breakthroughs, which have transformed the diagnosis, prognosis, and treatment of cancer.\u003cbr\u003e\u003cbr\u003eThe expert editor team and contributing authors provide an insightful overview to the novel therapeutic approaches targeting the molecular basis of cancer and allowing for the growth of precision medicine. This title is an essential resource for clinical and research oncologists and trainees, pharmacologic research and development professionals, biomedical scientists, and allied oncology professionals.\u003cbr\u003e\u003cbr\u003eTranslational Oncology Series\u003cbr\u003eSeries Editors\u003cbr\u003eROBERT C. BAST, MD\u003cbr\u003eVice President for Translational Research\u003cbr\u003eThe University of Texas MD Anderson Cancer Center\u003cbr\u003eHouston, TX, USA\u003cbr\u003e\u003cbr\u003eMAURIE MARKMAN, MD\u003cbr\u003eSenior Vice President for Clinical Affairs\u003cbr\u003eCancer Treatment Centers of America\u003cbr\u003eClinical Professor of Medicine\u003cbr\u003eDrexel University College of Medicine\u003cbr\u003ePhiladelphia, PA, USA\u003cbr\u003e\u003cbr\u003eERNEST HAWK, MD, MPH\u003cbr\u003eVice President, Division of OVP, Cancer Prevention and Population Sciences\u003cbr\u003eThe University of Texas MD Anderson Cancer Center\u003cbr\u003eHouston, TX, USA\u003cbr\u003e\u003cbr\u003eOther volumes in the \u003ci\u003eTranslational Oncology\u003c\/i\u003e Series\u003cbr\u003eCancer Gene Therapy by Viral and Non-viral Vectors\u003cbr\u003eEdited by Malcolm Brenner and Mien-Chie Hung\u003cbr\u003e978-1-118-50162-7\u003c\/p\u003e \u003cbr\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990132670693,"sku":"NP9781118468579","price":167.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118468579.jpg?v=1761786630","url":"https:\/\/k12savings.com\/es\/products\/targeted-therapy-in-translational-cancer-research-isbn-9781118468579","provider":"K12savings","version":"1.0","type":"link"}